Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer

Maria L. Macheda; Suzanne Rogers; James D. Best

doi:10.1002/jcp.20166

journal article Aug 17, 2004

Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer

Maria L. Macheda Suzanne Rogers James D. Best

Journal of Cellular Physiology Vol. 202 No. 3 pp. 654-662 · Wiley

View at Publisher Save 10.1002/jcp.20166

Abstract

AbstractMalignant cells are known to have accelerated metabolism, high glucose requirements, and increased glucose uptake. Transport of glucose across the plasma membrane of mammalian cells is the first rate‐limiting step for glucose metabolism and is mediated by facilitative glucose transporter (GLUT) proteins. Increased glucose transport in malignant cells has been associated with increased and deregulated expression of glucose transporter proteins, with overexpression of GLUT1 and/or GLUT3 a characteristic feature. Oncogenic transformation of cultured mammalian cells causes a rapid increase of glucose transport and GLUT1 expression via interaction with GLUT1 promoter enhancer elements. In human studies, high levels of GLUT1 expression in tumors have been associated with poor survival. Studies indicate that glucose transport in breast cancer is not fully explained by GLUT1 or GLUT3 expression, suggesting involvement of another glucose transporter. Recently, a novel glucose transporter protein, GLUT12, has been found in breast and prostate cancers. In human breast and prostate tumors and cultured cells, GLUT12 is located intracellularly and at the cell surface. Trafficking of GLUT12 to the plasma membrane could therefore contribute to glucose uptake. Several factors have been implicated in the regulation of glucose transporter expression in breast cancer. Hypoxia can increase GLUT1 levels and glucose uptake. Estradiol and epidermal growth factor, both of which can play a role in breast cancer cell growth, increase glucose consumption. Estradiol and epidermal growth factor also increase GLUT12 protein levels in cultured breast cancer cells. Targeting GLUT12 could provide novel methods for detection and treatment of breast and prostate cancer. © 2004 Wiley‐Liss, Inc.

Topics

No keywords indexed for this article. Browse by subject →

References

114

[1]

10.1309/5y2l-cdck-yb55-kdk6

[2]

10.1038/sj.bjp.0703829

[3]

10.1016/s0021-9258(18)54276-9

[4]

Avril N "Glucose metabolism of breast cancer assessed by 18F‐FDG PET: Histologic and immunohistochemical tissue analysis" J Nucl Med (2001)

[5]

10.1016/s0190-9622(97)70174-9

[6]

Baron‐Delage S "Deregulation of hexose transporter expression in Caco‐2 cells by ras and polyoma middle T oncogenes" Am J Physiol (1996)

[7]

10.1016/s0001-2998(84)80006-9

[8]

10.2337/diacare.13.3.198

[9]

Binder C "Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues" Anticancer Res (1997)

[10]

10.1073/pnas.83.16.5784

[11]

10.1126/science.3029870

[12]

10.1016/0960-0760(95)00005-k

[13]

10.1042/bj2650503

[14]

10.1200/jco.2002.20.2.379

[15]

10.1200/jco.2000.18.20.3535

[16]

10.1002/1097-0142(19931115)72:10<2979::aid-cncr2820721020>3.0.co;2-x

[17]

Brown RS "Intratumoral distribution of tritiated‐FDG in breast carcinoma: Correlation between Glut‐1 expression and FDG uptake" J Nucl Med (1996)

[18]

Brown RS "Glucose transporters and FDG uptake in untreated primary human non‐small cell lung cancer" J Nucl Med (1999)

[19]

10.1016/s0969-8051(02)00288-3

[20]

10.1021/bi00157a032

[21]

10.1016/s0021-9258(18)42067-4

[22]

Burgman P "Hypoxia‐Induced increase in FDG uptake in MCF7 cells" J Nucl Med (2001)

[23]

10.1038/sj.neo.7900147

[24]

10.1007/bf02616120

[25]

10.1002/1097-0142(20010901)92:5<1144::aid-cncr1432>3.0.co;2-t

[26]

10.1016/s0024-3205(99)00219-2

[27]

10.1002/cncr.11293

[28]

10.1016/0006-2952(94)00492-5

[29]

10.1074/jbc.m010144200

[30]

10.3349/ymj.1995.36.6.480

[31]

Chung JK "Mechanisms related to [18F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice" J Nucl Med (1999)

[32]

Clavo AC "Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia" J Nucl Med (1995)

[33]

10.1042/bj2900701

[34]

10.1006/mgme.2001.3212

[35]

10.1212/wnl.32.12.1323

[36]

Doege H "Activity and genomic organization of human glucose transporter 9 (GLUT9), a novel member of the family of sugar‐transport facilitators predominantly expressed in brain and leucocytes" Biochem J (2000) 10.1042/bj3500771

[37]

10.1074/jbc.275.21.16275

[38]

Doege H "Characterization of human glucose transporter (GLUT) 11 (encoded by SLC2A11), a novel sugar‐transport facilitator specifically expressed in heart and skeletal muscle" Biochem J (2001) 10.1042/bj3590443

[39]

Dutu R "Cytoenzymologic investigations on carcinomas of the cervix uteri" Acta Cytol (1980)

[40]

10.1074/jbc.270.49.29083

[41]

10.1126/science.3103217

[42]

Fukumoto H "Characterization and expression of human HepG2/erythrocyte glucose‐transporter gene" Diabetes (1988) 10.2337/diab.37.5.657

[43]

10.1021/bi00235a004

[44]

10.1007/bf02904704

[45]

10.1002/(sici)1097-0142(19980701)83:1<34::aid-cncr5>3.0.co;2-e

[46]

10.1038/sj.bjc.6600114

[47]

10.1097/00000658-200208000-00009

[48]

10.1016/0304-419x(74)90008-0

[49]

Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation

Gabriel Helmlinger, Fan Yuan, Marc Dellian et al.

Nature Medicine 10.1038/nm0297-177

[50]

10.1159/000217529

Showing 50 of 114 references

Cited By

987

Chemical Tomography of Cancer Organoids and Cyto‐Proteo‐Genomic Development Stages Through Chemical Communication Signals

Arnab Maity, Vivian Darsa Maidantchik · 2025

Advanced Materials

Improving Sorafenib Efficacy in HCC Tumour Cores via PDE5 Inhibitor‐Mediated Vasodilation in Hypoxic Microenvironments: Targeting the Glycolytic Pathway

Vinodinee Dubey, Raj Kumar Koiri · 2025

Journal of Biochemical and Molecula...

Tumor biomarkers for diagnosis, prognosis and targeted therapy

Yue Zhou, Lei Tao · 2024

Signal Transduction and Targeted Th...

Metabolic reprogramming in cancer: Mechanisms and therapeutics

Shiqi Nong, Xiaoyue Han · 2023

MedComm

α-Arrestins and Their Functions: From Yeast to Human Health

Kacper Zbieralski, Donata Wawrzycka · 2022

International Journal of Molecular...

An appraisal of the current status of inhibition of glucose transporters as an emerging antineoplastic approach: Promising potential of new pan-GLUT inhibitors

Mithlesh Kumar Temre, AJAY KUMAR · 2022

Frontiers in Pharmacology

Immunohistochemical Characterisation of GLUT1, MMP3 and NRF2 in Osteosarcoma

Catrin S. Rutland, James M. Cockcroft · 2021

Frontiers in Veterinary Science

NIR-II fluorescence imaging guided tumor-specific NIR-II photothermal therapy enhanced by starvation mediated thermal sensitization strategy

Yeneng Dai, Zhiquan Sun · 2021

Biomaterials

Metabolic Reprogramming in Triple-Negative Breast Cancer

Xiangyu Sun, Mozhi Wang · 2020

Frontiers in Oncology

Association of GRP78, HIF-1α and BAG3 Expression with the Severity of Chronic Lymphocytic Leukemia

Roghayeh Ijabi, Parisa Roozehdar · 2020

Anti-Cancer Agents in Medicinal Che...

How the Warburg effect supports aggressiveness and drug resistance of cancer cells?

Philippe Icard, Seth Shulman · 2018

Drug Resistance Updates

ESPEN guidelines on nutrition in cancer patients

Jann Arends, Patrick Bachmann · 2017

Clinical Nutrition

Glucose metabolic phenotype of pancreatic cancer

Anthony KC Chan, Jason IE Bruce · 2016

World Journal of Gastroenterology

Regulation of colonic epithelial butyrate transport: Focus on colorectal cancer

Pedro Goncalves, Fátima Martel · 2016

Porto Biomedical Journal

Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment

Calvin Justus, Edward Sanderlin · 2015

International Journal of Molecular...

Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality

Emily Jane Gallagher, Derek LeRoith · 2015

Physiological Reviews

Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma

Hideki Makinoshima, Masahiro Takita · 2015

Journal of Biological Chemistry

Tumor glycolysis as a target for cancer therapy: progress and prospects

Shanmugasundaram Ganapathy-Kanniappan, Jean-Francois H Geschwind · 2013

Molecular Cancer

Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma

Ai Mogi, Kaori Koga · 2012

Archiv für Pathologische Anatomie u...

Expression of GLUT1 and GLUT3 Glucose Transporters in Endometrial and Breast Cancers

Anna Krzeslak, Katarzyna Wojcik-Krowiranda · 2012

Pathology & Oncology Research

Metrics

987

Citations

114

References

Details

Published: Aug 17, 2004
Vol/Issue: 202(3)
Pages: 654-662
License: View

Authors

Cite This Article

Maria L. Macheda, Suzanne Rogers, James D. Best (2004). Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. Journal of Cellular Physiology, 202(3), 654-662. https://doi.org/10.1002/jcp.20166

Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer

You May Also Like